AUPN969796A0 - Taste masked liquid suspensions - Google Patents

Taste masked liquid suspensions

Info

Publication number
AUPN969796A0
AUPN969796A0 AUPN9697A AUPN969796A AUPN969796A0 AU PN969796 A0 AUPN969796 A0 AU PN969796A0 AU PN9697 A AUPN9697 A AU PN9697A AU PN969796 A AUPN969796 A AU PN969796A AU PN969796 A0 AUPN969796 A0 AU PN969796A0
Authority
AU
Australia
Prior art keywords
polymer
active ingredient
taste
pharmaceutically active
masked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPN9697A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
FH Faulding and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FH Faulding and Co Ltd filed Critical FH Faulding and Co Ltd
Priority to AUPN9697A priority Critical patent/AUPN969796A0/en
Publication of AUPN969796A0 publication Critical patent/AUPN969796A0/en
Priority to US09/180,354 priority patent/US6197348B1/en
Priority to DE69727386T priority patent/DE69727386T2/de
Priority to JP53935397A priority patent/JP4624498B2/ja
Priority to AU26270/97A priority patent/AU719137B2/en
Priority to AT97917939T priority patent/ATE258432T1/de
Priority to PCT/AU1997/000279 priority patent/WO1997041839A1/en
Priority to CA002253811A priority patent/CA2253811C/en
Priority to ES97917939T priority patent/ES2215223T3/es
Priority to DK97917939T priority patent/DK0921789T3/da
Priority to PT97917939T priority patent/PT921789E/pt
Priority to EP97917939A priority patent/EP0921789B1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AUPN9697A 1996-05-07 1996-05-07 Taste masked liquid suspensions Abandoned AUPN969796A0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AUPN9697A AUPN969796A0 (en) 1996-05-07 1996-05-07 Taste masked liquid suspensions
EP97917939A EP0921789B1 (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions
AU26270/97A AU719137B2 (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions
DE69727386T DE69727386T2 (de) 1996-05-07 1997-05-07 Geschmacksmaskierte flüssige suspensionen
JP53935397A JP4624498B2 (ja) 1996-05-07 1997-05-07 味隠蔽された懸濁液
US09/180,354 US6197348B1 (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions
AT97917939T ATE258432T1 (de) 1996-05-07 1997-05-07 Geschmacksmaskierte flüssige suspensionen
PCT/AU1997/000279 WO1997041839A1 (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions
CA002253811A CA2253811C (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions
ES97917939T ES2215223T3 (es) 1996-05-07 1997-05-07 Suspensiones liquidas de sabor enmascarado.
DK97917939T DK0921789T3 (da) 1996-05-07 1997-05-07 Væskesuspensioner med maskeret smag
PT97917939T PT921789E (pt) 1996-05-07 1997-05-07 Suspensoes liquidas de sabor mascarado

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9697A AUPN969796A0 (en) 1996-05-07 1996-05-07 Taste masked liquid suspensions

Publications (1)

Publication Number Publication Date
AUPN969796A0 true AUPN969796A0 (en) 1996-05-30

Family

ID=3794010

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPN9697A Abandoned AUPN969796A0 (en) 1996-05-07 1996-05-07 Taste masked liquid suspensions

Country Status (11)

Country Link
US (1) US6197348B1 (enExample)
EP (1) EP0921789B1 (enExample)
JP (1) JP4624498B2 (enExample)
AT (1) ATE258432T1 (enExample)
AU (1) AUPN969796A0 (enExample)
CA (1) CA2253811C (enExample)
DE (1) DE69727386T2 (enExample)
DK (1) DK0921789T3 (enExample)
ES (1) ES2215223T3 (enExample)
PT (1) PT921789E (enExample)
WO (1) WO1997041839A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
DE19809719A1 (de) 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
JP5420126B2 (ja) * 1999-02-04 2014-02-19 アボット・ラボラトリーズ ｐＨ非依存延長放出性医薬組成物
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
PT1616561E (pt) * 1999-12-28 2008-07-09 Ajinomoto Kk Preparação antidiabética para administração oral
HRP20020709A2 (en) * 2000-02-29 2004-12-31 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
NZ534746A (en) * 2002-03-12 2006-06-30 Bristol Myers Squibb Co Palatable oral suspension and method
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
CA2499550C (en) * 2002-09-20 2013-10-15 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040186180A1 (en) 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US7520489B2 (en) * 2003-06-17 2009-04-21 Filtertek Inc. Fluid handling device and method of making same
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20050163843A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
CA2552064A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
CA2577852A1 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
US7378109B2 (en) * 2004-12-23 2008-05-27 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
US20060205682A1 (en) * 2005-02-25 2006-09-14 Roberts Richard H Antibiotic and combinations of antibiotic and symptomatic relief agent formulations
BRPI0611272A2 (pt) * 2005-05-03 2011-11-16 Mutual Pharmaceutical Co formulações de quinina
CN1883456B (zh) * 2005-06-20 2010-12-15 常州市第四制药厂有限公司 掩味药物颗粒及其制备方法和用途
JP2007031407A (ja) * 2005-07-29 2007-02-08 Shin Etsu Chem Co Ltd 低置換度セルロースエーテル含有コーティング用組成物及び不快な味が隠蔽されたフィルムコーティング製剤
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
WO2007109057A2 (en) * 2006-03-16 2007-09-27 Novartis Ag Solid dosage form containing a taste masked active agent
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
EP2719378B1 (en) 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
KR20090094319A (ko) * 2006-12-26 2009-09-04 시오노기 앤드 컴파니, 리미티드 리스페리돈을 함유하는 구강내붕괴 정제 및 고미억제 제제
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8974827B2 (en) * 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709992A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Abuse resistant pharmaceutical compositions of opiod agonists
WO2010110018A1 (ja) 2009-03-27 2010-09-30 東レ株式会社 被覆固形製剤
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
SG183993A1 (en) * 2010-03-09 2012-10-30 Alkermes Pharma Ireland Ltd Alcohol resistant enteric pharmaceutical compositions
WO2013156163A1 (en) 2012-04-19 2013-10-24 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
WO2017057884A1 (ko) * 2015-09-30 2017-04-06 (주)아모레퍼시픽 자가회복 가능한 코어-쉘 캡슐
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
CN113181133A (zh) * 2021-04-25 2021-07-30 海南通用三洋药业有限公司 一种罗红霉素胶囊的制备方法
CN116687843A (zh) * 2022-12-16 2023-09-05 中国人民解放军军事科学院军事医学研究院 一种高稳定性的布瓦西坦溶液及其制备方法和其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
DE58903964D1 (de) * 1988-11-10 1993-05-06 Ciba Geigy Ag Fluessige orale formulierung.
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
JP3839467B2 (ja) * 1992-06-04 2006-11-01 スミスクライン・ビーチャム・コーポレイション 味の良い医薬組成物
AU6774694A (en) * 1993-04-26 1994-11-21 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids

Also Published As

Publication number Publication date
CA2253811C (en) 2006-10-24
EP0921789A4 (en) 2002-03-13
ATE258432T1 (de) 2004-02-15
DK0921789T3 (da) 2004-06-01
JP4624498B2 (ja) 2011-02-02
JP2000509399A (ja) 2000-07-25
DE69727386D1 (de) 2004-03-04
US6197348B1 (en) 2001-03-06
CA2253811A1 (en) 1997-11-13
PT921789E (pt) 2004-06-30
DE69727386T2 (de) 2004-11-11
EP0921789A1 (en) 1999-06-16
ES2215223T3 (es) 2004-10-01
WO1997041839A1 (en) 1997-11-13
EP0921789B1 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
AUPN969796A0 (en) Taste masked liquid suspensions
CA2089430A1 (en) Aqueous pharmaceutical suspension for pharmaceutical active
CA2019863A1 (en) Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
WO1995009619A3 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
EP1020460A3 (en) The sodium salt of the (-)-enantiomer of omeprazole
IE890906L (en) Method of lowering the blood pressure
CA2007181A1 (en) Sustained Release Pharmaceutical Composition
IL99183A0 (en) Water soluble derivatives of taxol,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2282345A1 (en) Pharmaceutical composition
EP0680328A1 (en) KETOCONAZOLE COMPOSITIONS FOR LOCAL USE.
AU3533395A (en) Oral sustained-release preparation
FR2766368B1 (fr) Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres
ATE374617T1 (de) Verfahren zur herstellung eines bluddrucksenkenden mittel enthaltenden ein dipeptid als wirksames bestandteil
PL345564A1 (en) Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose
EP0717992A3 (en) Aqueous suspension formulations for pharmaceutical applications
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
NO20022828D0 (no) Nye forgrenede substituerte aminoderivater av 3-amino-1-fenyl- 1H[1,2,4]triazol, fremgangsmåter for fremstilling av disse, ogfarmasöytiske preparater inneholdende disse
HUT75029A (en) Systems for controlled release of pilocarpine, and semipermeable capsule containing the active ingredient
WO2002076376A3 (en) A stable pharmaceutical composition of pravastatin
HK1045987A1 (zh) 3-氨基-2-苄基-1-苯基-丙烷衍生物
WO1997035568A3 (en) Diclofenac/gamma-cyclodextrin inclusion compounds
WO1998036732A3 (de) Kombinationspräparat für oral applizierbare antibiotika
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
EP1059304A4 (en) NOVEL POLYSACCHARIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITIONS CONTAINING THESE NEW DERIVATIVES AS ACTIVE INGREDIENT